Long‐term safety and efficacy of rIX‐FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B

An international, multicenter extension study evaluated recombinant fusion protein linking recombinant coagulation factor IX (FIX) with recombinant human albumin (rIX‐FP) in hemophilia B (FIX ≤ 2%) patients previously enrolled in a phase III study or who initiated rIX‐FP prophylaxis following surgery.

[1]  Songkai Yan,et al.  Assessing bleeding rates, related clinical impact and factor utilization in German hemophilia B patients treated with extended half-life rIX-FP compared to prior drug therapy , 2020, Current medical research and opinion.

[2]  L. Alberio,et al.  Systematic review and analysis of efficacy of recombinant factor IX products for prophylactic treatment of hemophilia B in comparison with rIX-FP , 2019, Journal of medical economics.

[3]  J. Gill,et al.  Sustained high trough factor IX activity levels with continued use of rIX‐FP in adult and paediatric patients with haemophilia B , 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

[4]  M. Morfini,et al.  Attempting to remedy sub-optimal medication adherence in haemophilia: The rationale for repeated ultrasound visualisations of the patient's joint status. , 2019, Blood reviews.

[5]  J. Oldenburg,et al.  Once‐weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9‐GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials , 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

[6]  G. Castaman.  The benefits of prophylaxis in patients with hemophilia B , 2018, Expert review of hematology.

[7]  J. Oldenburg,et al.  Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B. , 2016, Thrombosis and haemostasis.

[8]  E. Santagostino,et al.  Efficacy and safety of long‐acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[9]  K. Kuliczkowski,et al.  Once‐weekly prophylactic treatment vs. on‐demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[10]  J. Oldenburg,et al.  Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm™4). , 2016, Thrombosis research.

[11]  E. Santagostino,et al.  Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. , 2016, Blood.

[12]  J. Oldenburg,et al.  Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. , 2014, Blood.

[13]  R. Ljung,et al.  Definitions in hemophilia: communication from the SSC of the ISTH , 2014, Journal of thrombosis and haemostasis : JTH.

[14]  V. Jiménez‐Yuste,et al.  Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future. , 2014, Blood transfusion = Trasfusione del sangue.

[15]  M. Carcao.  Changing paradigm of prophylaxis with longer acting factor concentrates , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[16]  D. Grobbee,et al.  Outcome in moderate haemophilia. , 2014, Blood transfusion = Trasfusione del sangue.

[17]  J. Dumont,et al.  Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. , 2013, The New England journal of medicine.

[18]  L. Valentino,et al.  Association Of Bleeding Tendency With Time Under Target FIX Activity Levels In Severe Hemophilia B Patients Treated With Recombinant Factor IX Fc Fusion Protein , 2013 .

[19]  J. Mahlangu,et al.  Guidelines for the management of hemophilia , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[20]  M. Morfini,et al.  Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. , 2012, Blood.

[21]  M. Skinner.  WFH: Closing the global gap – achieving optimal care , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[22]  J. Astermark,et al.  Break‐through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A , 2009, Journal of thrombosis and haemostasis : JTH.

[23]  Alan R. Cohen,et al.  Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. , 2007, The New England journal of medicine.

[24]  M. Manco‐Johnson,et al.  Barriers to compliance with prophylaxis therapy in haemophilia , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

[25]  M. Morfini,et al.  The Design and Analysis of Pharmacokinetic Studies of Coagulation Factors , 2001 .

[26]  M. van den Berg,et al.  The Nijmegen Modification of the Bethesda Assay for Factor VIII:C Inhibitors: Improved Specificity and Reliability , 1995, Thrombosis and Haemostasis.

[27]  M. Morfini,et al.  The Design and Analysis of Half-Life and Recovery Studies for Factor VIII and Factor IX , 1991, Thrombosis and Haemostasis.